<?xml version="1.0" encoding="UTF-8"?>
<p>5-HT1A receptors control the antinausea effects of CBDA. In vivo mice study showed that CBDA inhibited vomiting caused by toxins and induced 5-HT1A receptor activity [
 <xref rid="B70-ijms-21-09049" ref-type="bibr">70</xref>,
 <xref rid="B71-ijms-21-09049" ref-type="bibr">71</xref>]. The pharmacokinetics of phytocannabinoid acids (including CBDA with others) showed that plasma level absorption occurred rapidly, and the brain/plasma ratio was very low. However, when CBDA was administered in an alternate Tween 80-based vehicle, the value of the brain/plasma ratio was 1.9 and in 
 <italic>Scn1a</italic>
 <sup>RX/+</sup> mouse model of Dravet syndrome, and CBDA showed potent anticonvulsant activity [
 <xref rid="B72-ijms-21-09049" ref-type="bibr">72</xref>].
</p>
